[ET Net News Agency, 8 February 2018] Luye Pharma (02186) said the Group's innovative
drug, Rotigotine Extended Release Microspheres for injection (LY03003), has been approved
by the Food and Drug Administration of the United States of America and is exempted from
Phase II dosage exploration clinical trials.
LY03003 is one of the Group's key central nervous system product candidates developed on
a long acting and extended-release formulation platform. The stable release of the drug in
the human body can reduce the "on-off" phenomenon common in drug treatments for patients
with Parkinson's disease, and significantly improves motor complications common among
patients with late-stage Parkinson's disease.
The drug is being concurrently developed in the markets of the U.S., China, Europe and
Japan, and has completed Phase I clinical trials in both China and the U.S.. (HL)